
    
      This is a multicenter, open-label, global study that will enroll patients who are currently
      receiving durvalumab monotherapy, or have previously received durvalumab as monotherapy or in
      combination with any other approved or investigational anticancer agents, in an eligible
      AstraZeneca/MedImmune-sponsored clinical study.
    
  